Almost 200 Stakeholders Attend the Final NAVMEC National Meeting to Make Recommendations About Implementation of "Next Generation" Veterinary Medical Education
July 19, 2010 10:26 ET
|
NAVMEC
LAS VEGAS, NV--(Marketwire - July 19, 2010) - The final of three national meetings to discuss the future of veterinary medical education concluded Friday after three days of presentations and...
"Research Advances from Therapeutic HIV Vaccines and Other Immune-Based Therapies" to Be Showcased at NAPWA Sponsored Community Treatment Research Forum at XVIII World AIDS Conference
July 13, 2010 13:45 ET
|
National Association of People with AIDS
SILVER SPRING, MD--(Marketwire - July 13, 2010) - The National Association of People with AIDS today announced that it is hosting a Community Treatment Research Forum, "Research Advances from...
Novogen Restructures Australian Management Team and Marshall Edwards Appoints CFO
June 18, 2010 09:00 ET
|
Novogen Limited
SYDNEY, AUSTRALIA--(Marketwire - June 18, 2010) - Novogen Limited's subsidiary, Marshall Edwards, Inc. (NASDAQ: MSHL), has announced today the appointment of Mr. Thomas Zech as its CFO and Company...
Marshall Edwards Announces Additional Management Changes With Appointment of New Chief Financial Officer
June 17, 2010 09:00 ET
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - June 17, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today...
Marshall Edwards' CEO to Present at Needham Healthcare Conference
June 03, 2010 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 3, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer...
Marshall Edwards Announces Final Results From Halted Phase 3 Clinical Trial of Phenoxodiol
June 01, 2010 08:31 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 1, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics,...
UPDATE: NutriPharma ASA and Subsidiary Bionor Immuno AS Change Name to Bionor Pharma ASA; New Board Selected by Shareholders at Annual General Meeting
May 27, 2010 10:48 ET
|
BionorPharma
OSLO, NORWAY--(Marketwire - May 27, 2010) - Norwegian Nutri Pharma ASA (OSLO: NUT) and its subsidiary Bionor Immuno AS today announced that the parent Company Nutri Pharma ASA will now be known...
Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Stockholders' Equity Non-Compliance
May 24, 2010 08:30 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - May 24, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics,...
Report on Phase II Clinical Study of Marshall Edwards' Phenoxodiol in Prostate Cancer to Be Presented at ASCO
May 21, 2010 09:00 ET
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - May 21, 2010) - Marshall Edwards, Inc., (NASDAQ: MSHL). An abstract titled "A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer...
Nutri Pharma ASA Adds New CFO to Commercialize Bionor Immuno Pipeline
May 10, 2010 12:17 ET
|
Nutri Pharma
OSLO, NORWAY and WASHINGTON, DC--(Marketwire - May 10, 2010) - Mr. Rolf Henning Lem has been appointed new CFO of Nutri Pharma ASA (OSLO: NUT). As part of his duties as CFO, Mr. Henning will...